Societal costs of ovarian cancer in a population-based cohort - a cost of illness analysis.

Indirect costs constituted a large part of the cost of illness over 6 years from diagnosis. This could indicate that even though treatment costs can be expected to rise with the introduction of new therapies, the societal cost may decrease when survival increase.